Unknown

Dataset Information

0

Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.


ABSTRACT: Zidovudine (AZT) remains the mainstay of antiretroviral therapy against HIV in resource-poor countries; however, its use is frequently associated with hepatotoxicity. Not all HIV patients on AZT develop hepatotoxicity, and the determining factors are unclear. Alcohol consumption and cigarette smoking are known risk factors for HIV hepatotoxicity, and both are significant sources of acrolein, a highly reactive and toxic aldehyde. This study examines the potential hepatotoxic interactions between acrolein and AZT. Our data demonstrate that acrolein markedly enhanced AZT-induced transcriptionally permissive histone modifications (H3K9Ac and H3K9Me3) allowing the recruitment of transcription factor NF-kB and RNA polymerase II at the FasL gene promoter, resulting in FasL upregulation and apoptosis in hepatocytes. Notably, the acrolein scavenger, hydralazine prevented these promoter-associated epigenetic changes and inhibited FasL upregulation and apoptosis induced by the combination of AZT and acrolein, as well as AZT alone. Our data strongly suggest that acrolein enhancement of promoter histone modifications and FasL upregulation are major pathogenic mechanisms driving AZT-induced hepatotoxicity. Moreover, these data also indicate the therapeutic potential of hydralazine in mitigating AZT hepatotoxicity.

SUBMITTER: Ghare SS 

PROVIDER: S-EPMC4938746 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3947461 | BioStudies
2020-01-01 | S-EPMC7532238 | BioStudies
1000-01-01 | S-EPMC190770 | BioStudies
2014-01-01 | S-EPMC4176051 | BioStudies
2012-01-01 | S-EPMC3283647 | BioStudies
2004-01-01 | S-EPMC434071 | BioStudies
1000-01-01 | S-EPMC4649230 | BioStudies
2015-01-01 | S-EPMC4604150 | BioStudies
2019-01-01 | S-EPMC6325205 | BioStudies
1000-01-01 | S-EPMC3608603 | BioStudies